GLP-1 for Men Over 50: What It Is and How It Works

Disclosure: This post contains affiliate links. If you purchase through them, we may earn a commission at no extra cost to you. We only recommend products that meet our evidence standard.

GLP-1 for men over 50 means a prescription medicine that mimics a hormone that helps regulate appetite. Two brand-name versions, Wegovy (semaglutide) and Zepbound (tirzepatide), are FDA-approved for weight management in adults with obesity, or with overweight plus at least one weight-related condition. A licensed clinician decides whether you qualify, and these are prescription drugs, not supplements.

This page covers what the FDA labels and the main trials say, and who those trials actually studied. It’s one piece of our weight loss for men over 50 guide. I won’t promise a number on the scale. Nobody can.

Table of Contents

What Is a GLP-1 Medication and How Does It Work?

GLP-1 is a hormone your body makes that helps regulate appetite and calorie intake. The Wegovy label says GLP-1 receptors sit in several areas of the brain involved in appetite regulation, and that semaglutide activates them.

Tirzepatide works on two targets. The Zepbound label calls it a GIP receptor and GLP-1 receptor agonist, and says nonclinical studies suggest the GIP part may further contribute to the regulation of food intake.

Which GLP-1 Drugs Are Approved, and for What?

Same molecule, different labels. Here are the main indications each FDA label lists.

Ozempic (semaglutide) is indicated to improve glycemic control in adults with type 2 diabetes. It is also indicated to lower the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to lower the risk of kidney function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Wegovy (semaglutide) is indicated, alongside a reduced-calorie diet and more physical activity, to reduce excess body weight and maintain weight reduction in adults with obesity, or with overweight plus a weight-related condition. It is also indicated to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight.
Mounjaro (tirzepatide) is indicated to improve glycemic control in adults and children 10 and older with type 2 diabetes.
Zepbound (tirzepatide) is indicated, alongside a reduced-calorie diet and more physical activity, for weight reduction in adults with obesity, or with overweight plus a weight-related condition. It is also indicated for moderate to severe obstructive sleep apnea in adults with obesity.

Want the two molecules side by side? Our semaglutide vs tirzepatide comparison goes through it.

Who Qualifies for GLP-1 Weight Loss Medications?

The labels tie weight-loss use to obesity, or to overweight with at least one weight-related condition. The label trial descriptions give hypertension and dyslipidemia as examples. The big trials enrolled adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition, and excluded people with diabetes. You don’t need type 2 diabetes for the weight-loss versions.

Both labels list who shouldn’t take the drug. That includes anyone with a personal or family history of medullary thyroid carcinoma, anyone with multiple endocrine neoplasia syndrome type 2, and anyone with a prior serious allergic reaction to the drug. Your clinician checks those before prescribing. For the full men’s weight loss picture, see GLP-1 weight loss for men.

Do GLP-1 Drugs Work for Men Over 50?

They lowered weight on average in adults in the trials, but those weight-loss trials enrolled mostly women with a mean age in the mid-40s, so the results aren’t a forecast for any one man over 50. Here is who was in them, according to the Wegovy and Zepbound labels.

The semaglutide trial (STEP 1) enrolled 1,961 adults without diabetes. Mean age was 46 and 74% were female.
The tirzepatide trial (SURMOUNT-1) enrolled 2,539 adults without diabetes. Mean age was 45 and 68% were female.
In the Wegovy weight-loss trials overall, 9% of people on Wegovy were 65 to 74 and 1% were 75 or older. In the two main Zepbound weight-loss studies, 9% were 65 or older.

The Zepbound label says weight reduction was observed irrespective of age, sex, race, ethnicity, baseline BMI and glycemic status. The Zepbound label also says no overall differences in safety or effectiveness were seen between patients 65 and older and younger adults. Both trials were funded by the drug makers, Novo Nordisk and Eli Lilly.

How Much Weight Did People Lose in the Big Trials?

In STEP 1, mean body weight fell 14.9% at 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo, with lifestyle intervention in both groups. In SURMOUNT-1, mean weight fell 15.0%, 19.5% and 20.9% at 72 weeks on tirzepatide 5, 10 and 15 mg versus 3.1% on placebo.

Those are group averages from people who also received diet and activity counseling. They don’t tell you what your own result will be, and treatment effects vary from person to person.

Can a GLP-1 Medication Help Men’s Heart Health?

One trial points that way for a specific group. In SELECT, 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or more, but no diabetes, got semaglutide 2.4 mg or placebo. Mean age was 62 and 72% were male.

A nonfatal heart attack, nonfatal stroke or cardiovascular death occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over an average of about 40 months of follow-up. That result applies to people who already had cardiovascular disease. It doesn’t show the same benefit for a healthy man using the drug for weight alone. Adverse events led 16.6% of the semaglutide group and 8.2% of the placebo group to permanently stop the study drug.

What Are the Side Effects and Risks of GLP-1 Drugs for Men Over 50?

Gastrointestinal effects are commonly reported. The Wegovy label lists nausea, diarrhea, vomiting, constipation and abdominal pain among its commonly reported adverse reactions. Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents. The Wegovy label says it’s unknown whether the drug causes these tumors in humans.

Both labels also warn about acute pancreatitis, acute gallbladder disease, acute kidney injury from dehydration after vomiting or diarrhea, diabetic retinopathy complications in people with type 2 diabetes, serious allergic reactions, and aspiration during anesthesia or deep sedation. Tell every provider about a planned surgery or procedure.

For older adults, the Wegovy label notes that in its cardiovascular outcomes trial, patients aged 75 and older on Wegovy reported more hip and pelvis fractures than patients on placebo, and patients 75 and older overall reported more serious adverse reactions than younger adults. Details, and what to ask your doctor, are in our GLP-1 side effects for men over 50 guide.

Will a GLP-1 Medication Cost Me Muscle?

Some lean mass can come off along with fat, and the labels and expert groups treat it as a real concern. The Wegovy and Zepbound labels both say the drug lowers body weight with greater fat mass loss than lean mass loss. A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society lists muscle and bone loss among the challenges of GLP-1 treatment. It recommends preserving muscle and bone mass through resistance training and appropriate diet.

My read: if you’re 50 or older, plan your strength training and protein before the first dose, not after the scale moves. The practical steps are in how to keep muscle on GLP-1.

Are Compounded GLP-1 Drugs the Same as Wegovy and Zepbound?

No. Wegovy and Zepbound are FDA-approved. Compounded versions are not. The FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed. The agency also reports receiving multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide (FDA page current as of October 1, 2026).

Some telehealth companies offer both kinds. Our compounded vs brand-name GLP-1 guide lays out the difference, and GobyMeds vs ShedRX compares two of the services.

How Do Men Over 50 Get a GLP-1 Prescription Online?

You complete an online health visit, and a licensed clinician reviews it. Telehealth makes the first step easier. It doesn’t change who decides.

ShedRX, whose site now redirects to Shed, is one of the services we’ve covered. Its page describes a 100% online visit and checkout, and lists compounded semaglutide and tirzepatide injections along with brand-name Wegovy and Zepbound. Its page also says compounded medications are not FDA-approved, and that a prescription follows a consultation with a licensed provider who determines whether treatment is appropriate. If you decide to try one, start with ShedRX’s online consultation and talk to your own doctor too. Bring your medication list and any personal or family history of thyroid cancer. Prices change, so check the current price on the provider’s page.

What Can’t a GLP-1 Do for You?

It doesn’t replace the basics. Both weight-loss labels say the drug is used in combination with a reduced-calorie diet and increased physical activity, and in STEP 1 and SURMOUNT-1 all participants got diet and activity counseling.

Where to Go Next

Start with the overview, weight loss for men over 50. Then read GLP-1 weight loss for men, GLP-1 side effects for men over 50, keeping muscle on GLP-1, compounded vs brand-name GLP-1, semaglutide vs tirzepatide and GobyMeds vs ShedRX.

Medical disclaimer: This page is for general information and is not medical advice. GLP-1 medications are prescription drugs. Talk to a licensed clinician about whether one is appropriate for you, and do not start, stop or change a medication without that conversation.

Frequently Asked Questions

Do I need type 2 diabetes to take a GLP-1 for weight loss?

No. The Wegovy and Zepbound labels cover adults with obesity, or overweight plus a weight-related condition, and the big weight-loss trials excluded people with diabetes. Ozempic and Mounjaro are the versions labeled for type 2 diabetes.

Is Ozempic the same as Wegovy?

Both contain semaglutide, but they have different FDA labels. Ozempic is indicated for type 2 diabetes and related risk reduction. Wegovy is indicated for weight management and for lowering cardiovascular risk in adults with established cardiovascular disease and obesity or overweight.

How much weight do men lose on GLP-1 drugs?

The labels don’t report a separate figure for men. In STEP 1, which was 74% female, average weight loss was 14.9% at 68 weeks with semaglutide 2.4 mg versus 2.4% on placebo. Individual results vary.

Who shouldn’t take a GLP-1 medication?

The Wegovy and Zepbound labels list contraindications: a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and a prior serious allergic reaction to the drug. Your clinician screens for these and for other conditions.

Can I take a GLP-1 without changing my diet or exercise?

The weight-loss labels describe use alongside a reduced-calorie diet and increased physical activity, and participants in STEP 1 and SURMOUNT-1 received counseling on both. Ask your clinician what plan fits you.

Sources